Victory Capital Management Inc. Increases Holdings in Biohaven Ltd. (NYSE:BHVN)

Victory Capital Management Inc. lifted its stake in Biohaven Ltd. (NYSE:BHVN) by 3.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 217,655 shares of the company’s stock after buying an additional 8,217 shares during the quarter. Victory Capital Management Inc.’s holdings in Biohaven were worth $7,555,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Biohaven by 280.5% during the first quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock valued at $345,031,000 after buying an additional 4,650,702 shares during the last quarter. Stifel Financial Corp boosted its stake in Biohaven by 7.9% during the 4th quarter. Stifel Financial Corp now owns 6,225,811 shares of the company’s stock valued at $266,465,000 after purchasing an additional 456,062 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Biohaven by 6.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,347,022 shares of the company’s stock worth $183,050,000 after purchasing an additional 212,699 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of Biohaven by 142.2% in the fourth quarter. Point72 Asset Management L.P. now owns 2,483,567 shares of the company’s stock worth $106,297,000 after purchasing an additional 1,458,072 shares during the last quarter. Finally, Perceptive Advisors LLC lifted its holdings in shares of Biohaven by 129.4% during the fourth quarter. Perceptive Advisors LLC now owns 1,725,047 shares of the company’s stock valued at $73,832,000 after purchasing an additional 973,227 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on BHVN shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $59.00 price objective on shares of Biohaven in a report on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a report on Monday, August 19th. William Blair upgraded shares of Biohaven to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reiterated a “buy” rating and set a $59.00 target price on shares of Biohaven in a research note on Thursday, May 30th. Finally, UBS Group lowered their price target on Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $54.44.

Insider Buying and Selling at Biohaven

In other Biohaven news, Director John W. Childs acquired 28,400 shares of the company’s stock in a transaction dated Thursday, July 18th. The stock was purchased at an average price of $35.67 per share, with a total value of $1,013,028.00. Following the completion of the purchase, the director now directly owns 2,339,741 shares in the company, valued at approximately $83,458,561.47. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 16.00% of the company’s stock.

Biohaven Trading Up 6.5 %

Shares of NYSE:BHVN opened at $38.08 on Monday. Biohaven Ltd. has a 12-month low of $16.45 and a 12-month high of $62.21. The company has a market cap of $3.60 billion, a PE ratio of -5.58 and a beta of 1.30. The stock has a 50 day moving average of $38.03 and a 200 day moving average of $41.34.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($3.64) EPS for the quarter, missing the consensus estimate of ($1.72) by ($1.92). Equities research analysts predict that Biohaven Ltd. will post -8.92 earnings per share for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.